421 related articles for article (PubMed ID: 29373094)
1. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
[TBL] [Abstract][Full Text] [Related]
2. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Shparyk Y; Moiseyenko V; Bello M; Semiglazov V; Lee Y; Lim J
Eur J Cancer; 2018 Apr; 93():19-27. PubMed ID: 29448072
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
Pivot X; Cortés J; Lüftner D; Lyman GH; Curigliano G; Bondarenko IM; Ahn JH; Im SA; Litwiniuk M; Shparyk YV; Ho GF; Kislov NV; Wojtukiewicz M; Sarosiek T; Chae YS; Ahn JS; Jang H; Kim S; Lee J; Yoon Y
JAMA Netw Open; 2023 Apr; 6(4):e235822. PubMed ID: 37022687
[TBL] [Abstract][Full Text] [Related]
4. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
[TBL] [Abstract][Full Text] [Related]
7. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
Berg T; Jensen MB; Jakobsen EH; Al-Rawi S; Kenholm J; Andersson M
Breast; 2020 Dec; 54():242-247. PubMed ID: 33186804
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
Nodehi RS; Kalantari B; Raafat J; Ansarinejad N; Moazed V; Mortazavizadeh SMR; Hosseinzadeh M; Ghaderi B; Jenabian A; Qadyani M; Haghighat S; Allahyari A; Mirzania M; Seghatoleslami M; Payandeh M; Alikhasi A; Kafi H; Shahi F
BMC Pharmacol Toxicol; 2022 Jul; 23(1):57. PubMed ID: 35902898
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA
BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305
[TBL] [Abstract][Full Text] [Related]
11. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
[TBL] [Abstract][Full Text] [Related]
13. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
Pivot X; Georgievich MA; Shamrai V; Dzagnidze G; Soo Hoo HF; Kaewkangsadan V; Petrelli F; Villanueva C; Nikolaevich LO; Hii J; Kim J; Pradhan S; Jaison L; Feyaerts P; Kaufman L; Derde MP; Bonamy GMC; Deforce F; Cox DG
JAMA Oncol; 2022 May; 8(5):698-705. PubMed ID: 35238873
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Li S; Wei W; Jiang Y; Li Q; Huang Q; Yang H; Liu J
Drug Des Devel Ther; 2018; 12():3085-3093. PubMed ID: 30275685
[TBL] [Abstract][Full Text] [Related]
19. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
Lammers PE; Dank M; Masetti R; Abbas R; Hilton F; Coppola J; Jacobs I
Br J Cancer; 2018 Aug; 119(3):266-273. PubMed ID: 30002437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
